Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.79, $0.13 better than the analyst estimate of $0.66. Revenue for the quarter came in at $390 million versus the consensus estimate of $376.01 million.

GUIDANCE:

Integra LifeSciences sees FY2021 EPS of $2.98-$3.05, versus the consensus of $2.92. Integra LifeSciences sees FY2021 revenue of $1.54-1.55 billion, versus the consensus of $1.53 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.